Aardvark Therapeutics launches its IPO, marking the first life science IPO of 2025 in San Diego, with its stock starting at $16 on Nasdaq. The company focuses on small molecule…
NKGen Biotech Takes Bold Financial Steps A recent loan to NKGen Biotech has raised eyebrows in the financial community, boasting an eye-popping annual interest rate of 12%. Initiated on December…
Kane Biotech has delivered impressive financial results, showcasing a promising turnaround. With revenue reaching CA$1.28 million, the company experienced a substantial increase of 79% over the previous quarter. This surge…
Kane Biotech's Stellar Q3 Performance Kane Biotech has announced its impressive financial results for the third quarter of 2024, highlighted by the celebrated commercial launch of their revyve™ Wound Gel.…